BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 22234349)

  • 1. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
    Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
    Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion.
    Vakiani E; Nandula SV; Subramaniyam S; Keller CE; Alobeid B; Murty VV; Bhagat G
    Hum Pathol; 2007 Feb; 38(2):315-25. PubMed ID: 17134734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR; Nalesnik MA; Swerdlow SH
    Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment.
    Chan TS; Hwang YY; Gill H; Au WY; Leung AY; Tse E; Chim CS; Loong F; Kwong YL
    Clin Transplant; 2012; 26(5):679-83. PubMed ID: 22324300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
    Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
    Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients.
    Babel N; Vergopoulos A; Trappe RU; Oertel S; Hammer MH; Karaivanov S; Schneider N; Riess H; Papp-Vary M; Neuhaus R; Gondek LP; Volk HD; Reinke P
    Transplantation; 2007 Aug; 84(3):387-91. PubMed ID: 17700165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder?
    Gibson SE; Swerdlow SH; Craig FE; Surti U; Cook JR; Nalesnik MA; Lowe C; Wood KM; Bacon CM
    Am J Surg Pathol; 2011 Jun; 35(6):807-15. PubMed ID: 21552113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities.
    Djokic M; Le Beau MM; Swinnen LJ; Smith SM; Rubin CM; Anastasi J; Carlson KM
    Genes Chromosomes Cancer; 2006 Mar; 45(3):313-8. PubMed ID: 16283619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.